血清Stathmin、TFF3与上皮性卵巢癌患者初始肿瘤细胞减灭术治疗结局和术后复发的关系  

Association of serum Stathmin and TFF3 with treatment outcome and postoperative recurrence after initial cytoreductive surgery in patients with epithelial ovarian cancer

作　　者：韩晴[1] 何爱琴[1] 李咏 邱云芬[1] 刘春花[1] HAN Qing;HE Aiqin;LI Yong;QIU Yunfen;LIU Chunhua(Department of Gynaecology,Nantong Tumor Hospital/Cancer Hospital of Nantong University,Nantong,Jiangsu 226361,China)

机构地区：[1]南通市肿瘤医院/南通大学附属肿瘤医院妇科,江苏南通226361

出　　处：《国际检验医学杂志》2023年第23期2848-2853,共6页International Journal of Laboratory Medicine

基　　金：国家重点研发计划课题(2019YFC0907462)。

摘　　要：目的研究血清微管解聚蛋白(Stathmin)、三叶因子3(TFF3)与上皮性卵巢癌患者初始肿瘤细胞减灭术治疗结局和术后复发的关系。方法选取2016年7月至2020年1月该院收治的177例上皮性卵巢癌患者,收集患者的临床资料,采用酶联免疫吸附试验检测Stathmin、TFF3水平。根据手术结局将患者分为满意组和不满意组,采用受试者工作特征(ROC)曲线分析血清Stathmin联合TFF3对治疗结局不满意的预测价值;统计手术治疗满意患者的复发情况,根据是否复发分为复发组和未复发组,采用单因素及多因素Logistic回归模型分析影响患者术后复发的危险因素,并分析血清Stathmin联合TFF3对术后复发的预测价值。结果手术治疗结局满意113例(满意组),不满意64例(不满意组)。满意组血清Stathmin、TFF3水平低于不满意组(t=-14.302、-8.405,P<0.05)。血清Stathmin联合TFF3预测治疗结局不满意的曲线下面积(AUC)为0.826,灵敏度为78.1%、特异度为83.2%,预测效能高于Stathmin、TFF3单独检测。复发患者47例(复发组),未复发66例(未复发组)。多因素Logistic回归分析显示,术前血清Stathmin、TFF3水平升高为患者术后复发的独立危险因素[OR(95%CI)=3.402(1.599~7.231)、1.031(1.014~1.049),P<0.05]。血清Stathmin联合TFF3联合预测术后复发的AUC为0.834,灵敏度为80.9%、特异度为83.3%,预测效能高于Stathmin、TFF3单独检测。结论血清Stathmin、TFF3水平在上皮性卵巢癌患者中异常升高且与初始肿瘤细胞减灭术治疗结局和术后复发有关。Objective To investigate the correlation of serum microtubule depolymerizing protein(Stathmin)and trefoil factor 3(TFF3)with the outcome and recurrence of epithelial ovarian cancer after initial cytoreductive surgery.Methods A total of 177 patients with epithelial ovarian cancer admitted to the hospital from July 2016 to January 2020 were selected,and their clinical data were collected.The levels of Stathmin and TFF3 were detected by enzyme-linked immunosorbent assay.The patients were divided into satisfactory group and unsatisfactory group according to the surgical outcome.Receiver operating characteristic(ROC)curve was used to analyze the predictive value of serum Stathmin combined with TFF3 for unsatisfactory treatment outcome.The recurrence of patients with satisfactory surgical treatment was analyzed.The patients were divided into recurrence group and non-recurrence group according to the presence or absence of recurrence.Univariate and multivariate Logistic regression models were used to analyze the risk factors affecting postoperative recurrence.The predictive value of serum Stathmin combined with TFF3 for postoperative recurrence was analyzed.Results A total of 113 patients were satisfied with the surgical treatment outcome(satisfactory group)and 64 patients were not satisfied(unsatisfactory group).The serum levels of Stathmin and TFF3 in the satisfactory group were lower than those in the unsatisfactory group(t=-14.302,-8.405,P<0.05).The area under the curve(AUC)of serum Stathmin combined with TFF3 for predicting unsatisfactory treatment outcome was 0.826,with a sensitivity of 78.1%and a specificity of 83.2%.The predictive efficacy of serum Stathmin combined with TFF3 was higher than Stathmin or TFF3 alone.There were 47 patients with recurrence(recurrence group)and 66 patients without recurrence(non-recurrence group).Multivariate Logistic regression analysis showed that the increase of preoperative serum Stathmin and TFF3 levels were independent risk factors for postoperative recurrence[OR(95%CI)=3.402(1

关 键 词：上皮性卵巢癌 微管解聚蛋白 三叶因子3 初始肿瘤细胞减灭术 

分 类 号：R737.31[医药卫生—肿瘤]